A clinical-stage biotechnology company focused on developing therapeutics that target mast cell and hematopoietic stem cell-driven diseases, with lead product candidate briquilimab designed to treat conditions including chronic urticaria, asthma, and to serve as a conditioning agent for stem cell transplants.